• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Veracyte Announces Multiple Abstracts To Be Presented at ASCO, Demonstrating Power of Decipher GRID to Advance New Prostate and Bladder Cancer Research

    5/28/25 4:05:00 PM ET
    $VCYT
    Medical Specialities
    Health Care
    Get the next $VCYT alert in real time by email

     

    Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced that eight abstracts featuring data derived from testing with its Decipher Prostate and Decipher Bladder genomic classifiers will be presented at ASCO, the annual meeting of the American Society of Clinical Oncology, being held May 30-June 3 in Chicago. Key findings shed new light on which patients with prostate or bladder cancer may be more likely to respond to specific therapies based on their tumors' molecular make-up.

    "These new findings underscore the power of our whole-transcriptome-based Decipher GRID, or Genomic Resource for Intelligent Discovery, research tool to help advance understanding of urologic cancers at the molecular level," said Phil Febbo, M.D., Veracyte's chief scientific officer and chief medical officer. "We are pleased to share this resource with the research community to help reveal new insights that could one day enable more-personalized care and outcomes for patients with prostate or bladder cancer."

    The following Decipher Prostate GRID-focused abstract will be shared in a podium presentation at the McCormick Place convention center:

    Title:

    Transcriptome classification of PTEN inactivation to predict survival benefit from docetaxel at start of androgen deprivation therapy (ADT) for metastatic prostate cancer (PC): an ancillary study of the STAMPEDE trials.

    Presenter:

    Emily Grist, Ph.D., University College London Cancer Institute

    Format:

    Oral Abstract Presentation

    Abstract #:

    5003

    Date/Time:

    Tuesday, June 3; 9:45 a.m. – 12:45 p.m. CDT

    Room:

    Hall D

    Researchers found that patients whose metastatic prostate cancer had a PTEN-inactive gene expression signature were more likely to benefit from the addition of the chemotherapy, docetaxel, to standard androgen deprivation therapy (ADT), compared to those with PTEN-active tumors. Specifically, the PTEN-inactive patients had a 43% reduction in risk of death (HR=0.57, 95% 0.42-0.76), unlike PTEN-active patients where no benefit from docetaxel was observed (HR=1.05, 95% CI 0.77-1.43), with a significant interaction observed between docetaxel and PTEN status (p=0.002). Additionally, docetaxel benefited patients with PTEN-inactive tumors regardless of whether they had high- or low-volume prostate cancer. Finally, patients with tumors that were both PTEN-inactive and had high Decipher Prostate test risk scores had the greatest benefit from the addition of chemotherapy.

    The study involved 832 patients with metastatic prostate cancer who were followed for a median of 14 years as part of STAMPEDE—a large, multi-center, randomized Phase 3 clinical trial that aims to determine the best way to treat men with newly diagnosed advanced or metastatic prostate cancer. Previously presented data showed that patients with high Decipher Prostate Genomic Classifier risk scores were more likely to benefit from the addition of docetaxel to ADT, compared to those with low Decipher test scores.1

    "It's well known that adding docetaxel to ADT increases survival for some patients with metastatic prostate cancer. The challenge has been knowing which patients will benefit and which ones will not so the latter can avoid unnecessary toxicity," said Emily Grist, Ph.D., of the University College London Cancer Institute who will present the new findings at the ASCO meeting. "Our results help to further elucidate molecular features of advanced prostate cancer, which may help us better select treatments for our patients."

    The following Decipher Bladder GRID-focused abstract will be shared in a podium presentation at the ASCO meeting:

    Title:

    First results of SURE-02: A Phase 2 study of Neoadjuvant Sacituzumab Govitecan (SG) plus Pembrolizumab (Pembro), followed by response-adapted bladder sparing and adjuvant Pembro, in patients with muscle-invasive bladder cancer (MIBC)

    Presenter:

    Andrea Necchi, M.D., IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy

    Format:

    Rapid Oral Abstract Presentation

    Abstract #:

    4518

    Date/Time:

    Saturday, May 31; 1:15 – 2:45 p.m. CDT

    Room:

    Arie Crown Theater

    This study evaluated whether patients with muscle-invasive bladder cancer (MBIC) could potentially benefit from treatment with Sacituzumab Govitecan (SG) plus Pembrolizumab (Pembro), rather than standard-of-care chemotherapy, prior to radical cystectomy (RC). It also used the Decipher Bladder GRID research tool to identify patients who were more likely to achieve clinical complete response (cCR), based on the molecular underpinnings of their tumor.

    "Interim results from SURE-02 trial revealed that neoadjuvant Sacituzumab Govitecan plus Pembrolizumab, followed by bladder sparing in complete responders and maintenance pembrolizumab was a safe and effective strategy in patients with MIBC," said Andrea Necchi, M.D., of IRCCS San Raffaele Hospital and Vita-Salute San Raffaele University in Milan, Italy, who presented the findings. "Preliminary biomarker data developed by Veracyte as part of its Decipher Bladder test and GRID research tool, revealed associations between Luminal subtype and clinical complete response, or cCR, and immune signatures linked to the EFS gene that could ultimately help improve outcomes in molecularly-selected patients."

    A more complete list of Decipher-focused abstracts to be presented at the ASCO meeting can be found on Veracyte's website here.

    About Decipher GRID

    The Decipher GRID database includes more than 200,000 whole-transcriptome profiles from patients with urologic cancers and is used by Veracyte and its partners to contribute to continued research and help advance understanding of prostate and other urologic cancers. GRID-derived information is available on a Research Use Only basis. More information about Decipher GRID can be found here.

    About Decipher Prostate

    The Decipher Prostate Genomic Classifier is a 22-gene test, developed using RNA whole-transcriptome analysis and machine learning, that helps inform treatment decisions for patients across the full spectrum of prostate cancer. The test is performed on biopsy or surgically resected samples and conveys the aggressiveness of the cancer. For patients with localized or regional prostate cancer, the Decipher score indicates a patient's risk of metastasis, helping to determine treatment timing and intensity. For patients with metastatic prostate cancer, the Decipher score indicates the likelihood of cancer progression and survival benefit with treatment intensification. Armed with this information, physicians can better personalize their patients' care. The Decipher Prostate test's performance and clinical utility has been demonstrated in over 90 studies involving more than 200,000 patients. It is the only gene expression test to achieve "Level I" evidence status and inclusion in the risk-stratification table in the most recent NCCN® Guidelines* for prostate cancer. More information about the Decipher Prostate test can be found here.

    About Decipher Bladder

    The Decipher Bladder Genomic Classifier is a 219-gene test, developed using RNA whole-transcriptome analysis and machine learning, that is designed for use in patients following bladder cancer diagnosis who face questions regarding treatment intensity. The test classifies bladder tumors into five molecular subtypes, each having distinct tumor biology and potential clinical implications. This information can help physicians and their patients better understand the degree of benefit that would likely be gained from neoadjuvant chemotherapy and/or the likelihood of harboring non-organ-confined disease at time of surgery, respectively. More information about the Decipher Bladder test can be found here.

    About Veracyte

    Veracyte (NASDAQ:VCYT) is a global diagnostics company whose vision is to transform cancer care for patients all over the world. We empower clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our Veracyte Diagnostics Platform delivers high-performing cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and a powerful evidence-generation engine, which ultimately drives durable reimbursement and guideline inclusion for our tests, along with new insights to support continued innovation and pipeline development. For more information, please visit www.veracyte.com or follow us on LinkedIn or X (Twitter).

    Cautionary Note Regarding Forward-Looking Statements

    This press release contains forward-looking statements, including, but not limited to our statements related to the potential power of Decipher Prostate and Decipher Bladder genomic classifiers to help advance understanding of urologic cancers at the molecular level; help reveal new insights that could one day enable more-personalized care and outcomes for patients with prostate or bladder cancer; that key findings shed new light on which patients with prostate or bladder cancer may be more likely to respond to specific therapies based on their tumors' molecular make-up; that our results help to further elucidate the molecular features of advanced prostate cancer, which may help us better select treatments for our patients; and that the Decipher Bladder test and GRID research tool revealed associations between Luminal subtype and clinical complete response and immune signatures linked to the EFS gene that could ultimately help improve outcomes in molecularly-selected patients. Forward-looking statements can be identified by words such as: "appears," "anticipate," "intend," "plan," "expect," "believe," "should," "may," "will," "enable," "positioned," "offers," "designed," "ultimately," and similar references to future periods. Actual results may differ materially from those projected or suggested in any forward-looking statements. These statements involve risks and uncertainties, which could cause actual results to differ materially from our predictions, and include, but are not limited to the potential impact the Veracyte Diagnostics Platform can have on scientific advancements in cancer and, in turn, patient care. Additional factors that may impact these forward-looking statements can be found under the caption "Risk Factors" in our Annual Report on Form 10-K filed on February 28, 2025. Copies of these documents, when available, may be found in the Investors section of our website at https://investor.veracyte.com. These forward-looking statements speak only as of the date hereof and, except as required by law, we specifically disclaim any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise.

    1 Grist et al. Decipher mRNA score for prediction of survival benefit from docetaxel at start of androgen deprivation therapy (ADT) for advanced prostate cancer (PC): An ancillary study of the STAMPEDE docetaxel trials. Presented at: Proffered paper session: GU tumors, prostate; ESMO Congress 2024; 2024 Sep; Barcelona, Spain.

    Veracyte, the Veracyte logo, and Decipher are registered trademarks of Veracyte, Inc., and its subsidiaries in the U.S. and selected countries.

    * National Comprehensive Cancer Network. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250528532573/en/

    Investors:

    Shayla Gorman

    [email protected]

    619-393-1545

    Media:

    Tracy Morris

    [email protected]

    650-380-4413

    Get the next $VCYT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VCYT

    DatePrice TargetRatingAnalyst
    3/20/2025$45.00Buy
    Craig Hallum
    12/5/2024$38.00 → $37.00Buy → Neutral
    Goldman
    11/15/2024$50.00Outperform
    Wolfe Research
    10/16/2024$43.00Buy
    UBS
    10/10/2024$40.00Buy
    Guggenheim
    2/23/2024$30.00 → $33.00Buy
    Needham
    1/18/2023Outperform → Mkt Perform
    Raymond James
    1/5/2023$33.00Sector Outperform
    Scotiabank
    More analyst ratings

    $VCYT
    Financials

    Live finance-specific insights

    See more
    • Veracyte Announces First Quarter 2025 Financial Results

      Strong testing volume growth resulted in total revenue of $114.5 million, an increase of 18% Conference call and webcast today at 4:30 p.m. ET Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced financial results for the first quarter ended March 31, 2025. "We started 2025 with the eleventh consecutive quarter of 20% or more testing volume growth, driven by strong Decipher and Afirma demand," said Marc Stapley, Veracyte's chief executive officer. "With solid Q1 results and Decipher now available for metastatic prostate cancer patients, we are well positioned to deliver on our expectations for this year and beyond, especially given our recent successes in a

      5/7/25 4:05:00 PM ET
      $VCYT
      Medical Specialities
      Health Care
    • Veracyte to Release First Quarter 2025 Financial Results on May 7, 2025

      Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the first quarter of 2025 after the close of market on Wednesday, May 7, 2025. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. The conference call will be webcast live from the company's website and will be available via the following link: https://edge.media-server.com/mmc/p/5r4msrbq. A webcast replay will be available following the conclusion of the live broadcast and will be accessible on the company's website at https://investor.veracyte.com/

      4/16/25 6:30:00 PM ET
      $VCYT
      Medical Specialities
      Health Care
    • Veracyte Announces Fourth Quarter and Full Year 2024 Financial Results

      Grew fourth quarter total revenue to $118.6 million, an increase of 21% Grew fourth quarter testing revenue to $112.2 million, an increase of 24% Conference call and webcast today at 4:30 p.m. ET Veracyte, Inc. (NASDAQ:VCYT) today announced financial results for the fourth quarter and full year ended December 31, 2024. "I'm incredibly proud of what our team accomplished in 2024," said Marc Stapley, Veracyte's chief executive officer. "We ended the year with exceptional performance, delivering record revenue in Q4 and achieving our 10th consecutive quarter of 20% or greater testing revenue growth. Looking ahead to 2025, we see significant opportunities for Decipher and Afirma to impact

      2/24/25 4:05:00 PM ET
      $VCYT
      Medical Specialities
      Health Care

    $VCYT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Craig Hallum initiated coverage on Veracyte with a new price target

      Craig Hallum initiated coverage of Veracyte with a rating of Buy and set a new price target of $45.00

      3/20/25 7:42:48 AM ET
      $VCYT
      Medical Specialities
      Health Care
    • Veracyte downgraded by Goldman with a new price target

      Goldman downgraded Veracyte from Buy to Neutral and set a new price target of $37.00 from $38.00 previously

      12/5/24 8:24:30 AM ET
      $VCYT
      Medical Specialities
      Health Care
    • Wolfe Research initiated coverage on Veracyte with a new price target

      Wolfe Research initiated coverage of Veracyte with a rating of Outperform and set a new price target of $50.00

      11/15/24 8:25:09 AM ET
      $VCYT
      Medical Specialities
      Health Care

    $VCYT
    Leadership Updates

    Live Leadership Updates

    See more
    • Veracyte Appoints Brent Shafer and Tom Miller, Ph.D., to Its Board of Directors

      Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced the appointment of Brent Shafer and Tom Miller, Ph.D., to its board of directors, effective immediately. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240904531409/en/New Veracyte board member Brent Shafer. (Photo: Business Wire) "We are thrilled to welcome Brent and Tom to our board," said Marc Stapley, Veracyte's chief executive officer. "They are both seasoned business leaders with extensive healthcare industry experience who will further broaden our board's mix of backgrounds and expertise." Mr. Shafer brings over 40 years of experience ac

      9/4/24 4:05:00 PM ET
      $VCYT
      Medical Specialities
      Health Care
    • Veracyte Names Phillip G. Febbo, M.D., as Chief Scientific Officer and Chief Medical Officer

      Veracyte, Inc. (NASDAQ:VCYT) today announced that Phillip G. Febbo, M.D., will join the company on October 2 as chief scientific officer and chief medical officer. Dr. Febbo, a distinguished industry and academic leader, will lead Veracyte's global team of research and development, medical affairs, clinical affairs, quality, regulatory affairs, and lab director professionals to help advance novel tests that address important unmet patient-care needs in cancer. He will report to Marc Stapley, Veracyte's chief executive officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230927846710/en/Veracyte Names Phillip G. Febbo, M.D., a

      9/27/23 9:00:00 AM ET
      $VCYT
      Medical Specialities
      Health Care
    • Veracyte Appoints Eliav Barr, M.D., to Its Board of Directors

      Veracyte, Inc. (NASDAQ:VCYT) today announced the appointment of Eliav Barr, M.D., to its board of directors, effective immediately. "We are thrilled to welcome Eliav Barr to our board," said Marc Stapley, Veracyte's chief executive officer. "Dr. Barr has exceptional global biopharmaceutical industry experience, which will be key to helping us achieve our ambition of improving outcomes for patients all over the world. We are also eager to benefit from his expertise in our efforts to further expand our biopharmaceutical partnerships by leveraging our data assets and multi-omics capabilities, particularly in immuno-oncology." Dr. Barr has built his distinguished career at Merck Research Labo

      8/11/22 4:05:00 PM ET
      $VCYT
      Medical Specialities
      Health Care

    $VCYT
    SEC Filings

    See more
    • SEC Form 10-Q filed by Veracyte Inc.

      10-Q - VERACYTE, INC. (0001384101) (Filer)

      5/8/25 8:06:25 AM ET
      $VCYT
      Medical Specialities
      Health Care
    • Veracyte Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - VERACYTE, INC. (0001384101) (Filer)

      5/7/25 4:07:43 PM ET
      $VCYT
      Medical Specialities
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Veracyte Inc.

      SCHEDULE 13G/A - VERACYTE, INC. (0001384101) (Subject)

      5/7/25 10:59:51 AM ET
      $VCYT
      Medical Specialities
      Health Care

    $VCYT
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $VCYT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Veracyte Announces Multiple Abstracts To Be Presented at ASCO, Demonstrating Power of Decipher GRID to Advance New Prostate and Bladder Cancer Research

        Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced that eight abstracts featuring data derived from testing with its Decipher Prostate and Decipher Bladder genomic classifiers will be presented at ASCO, the annual meeting of the American Society of Clinical Oncology, being held May 30-June 3 in Chicago. Key findings shed new light on which patients with prostate or bladder cancer may be more likely to respond to specific therapies based on their tumors' molecular make-up. "These new findings underscore the power of our whole-transcriptome-based Decipher GRID, or Genomic Resource for Intelligent Discovery, research tool to help advance understanding of

      5/28/25 4:05:00 PM ET
      $VCYT
      Medical Specialities
      Health Care
    • Veracyte to Participate in Upcoming Investor Conferences

      Veracyte, Inc. (NASDAQ:VCYT) a leading cancer diagnostics company, announced today it will participate in the following investor conferences. William Blair 45th Annual Growth Stock Conference – Chicago, IL Presentation on June 3rd at 5:40 p.m. Eastern Time Jefferies Global Healthcare Conference – New York, NY Presentation on June 4th at 2:00 p.m. Eastern Time Live audio webcasts of the company's presentations will be available by visiting Veracyte's website at http://investor.veracyte.com/events-presentations. Replays of the webcasts will be available for 90 days after each live presentation broadcast. About Veracyte Veracyte (NASDAQ:VCYT) is a global diagnostics company whose visi

      5/20/25 5:00:00 PM ET
      $VCYT
      Medical Specialities
      Health Care
    • Veracyte Announces First Quarter 2025 Financial Results

      Strong testing volume growth resulted in total revenue of $114.5 million, an increase of 18% Conference call and webcast today at 4:30 p.m. ET Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced financial results for the first quarter ended March 31, 2025. "We started 2025 with the eleventh consecutive quarter of 20% or more testing volume growth, driven by strong Decipher and Afirma demand," said Marc Stapley, Veracyte's chief executive officer. "With solid Q1 results and Decipher now available for metastatic prostate cancer patients, we are well positioned to deliver on our expectations for this year and beyond, especially given our recent successes in a

      5/7/25 4:05:00 PM ET
      $VCYT
      Medical Specialities
      Health Care
    • SEC Form SC 13G filed by Veracyte Inc.

      SC 13G - VERACYTE, INC. (0001384101) (Subject)

      11/12/24 9:30:49 AM ET
      $VCYT
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Veracyte Inc.

      SC 13G/A - VERACYTE, INC. (0001384101) (Subject)

      11/8/24 10:41:07 AM ET
      $VCYT
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Veracyte Inc.

      SC 13G/A - VERACYTE, INC. (0001384101) (Subject)

      10/2/24 2:12:30 PM ET
      $VCYT
      Medical Specialities
      Health Care

    $VCYT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • VP, Chief Accounting Officer Wygant Jonathan was granted 13,288 shares, increasing direct ownership by 36% to 49,763 units (SEC Form 4)

      4 - VERACYTE, INC. (0001384101) (Issuer)

      3/10/25 4:44:25 PM ET
      $VCYT
      Medical Specialities
      Health Care
    • Chief Scientific & Med Officer Febbo Phillip G. was granted 24,160 shares, increasing direct ownership by 29% to 106,700 units (SEC Form 4)

      4 - VERACYTE, INC. (0001384101) (Issuer)

      3/10/25 4:44:13 PM ET
      $VCYT
      Medical Specialities
      Health Care
    • Chief Financial Officer Chambers Rebecca was granted 30,200 shares, increasing direct ownership by 27% to 143,899 units (SEC Form 4)

      4 - VERACYTE, INC. (0001384101) (Issuer)

      3/10/25 4:44:02 PM ET
      $VCYT
      Medical Specialities
      Health Care